Boothbay Fund Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Boothbay Fund Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,100	Closed	-$920K	–	2254
2022 Q2	$920K	Sell	11,100 -57,100	-84%	-$4.55M	0.02%	859
2022 Q1	$5.26M	Buy	68,200 +57,100	+514%	+$4.78M	0.12%	198
2021 Q4	$981K	Buy	+11,100	New	+$916K	0.02%	761
2021 Q2	–	Sell	-75	Closed	-$566K	–	1854
2021 Q1	$566K	Buy	+75	New	+$6.13K	0.02%	870
2020 Q3	–	Sell	-47	Closed	-$580K	–	1049
2020 Q2	$580K	Sell	47 -64	-58%	-$6.36K	0.04%	536
2020 Q1	$938K	Buy	+111	New	+$9.56K	0.08%	317
2016 Q2	–	Sell	-4,800	Closed	-$396K	–	511
2016 Q1	$396K	Buy	+4,800	New	+$391K	0.3%	103

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's BMRN Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 34,206 shares worth $1.93M. The stake represents 0.03% of the portfolio and ranks #642 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in BMRN as recently as Q3 2025.

Boothbay Fund Management first reported a position in BMRN in Q1 2017 and has held it in 12 quarters since. The position peaked at $2.51M in Q1 2023. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Boothbay Fund Management held 34,206 shares of BioMarin Pharmaceuticals worth $1.93M as of Q1 2026.
BioMarin Pharmaceuticals was a new Boothbay Fund Management position in Q1 2026.
BioMarin Pharmaceuticals made up 0.03% of Boothbay Fund Management's portfolio in Q1 2026, its #642 holding.
Boothbay Fund Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 12 quarters since.
Boothbay Fund Management's BioMarin Pharmaceuticals position peaked at $2.51M in Q1 2023.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.